

David K Simon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9475963/publications.pdf>

Version: 2024-02-01

74
papers

7,022
citations

87888

38
h-index

85541

71
g-index

76
all docs

76
docs citations

76
times ranked

10671
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional Coactivators. <i>Cell</i> , 2006, 127, 397-408. | 28.9 | 1,948 |
| 2 | Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. <i>Clinics in Geriatric Medicine</i> , 2020, 36, 1-12. | 2.6 | 487 |
| 3 | High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. <i>Human Molecular Genetics</i> , 2002, 11, 133-145. | 2.9 | 318 |
| 4 | A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 543. | 9.0 | 312 |
| 5 | Meta-analysis of Parkinson's Disease: Identification of a novel locus, <i>RIT2</i> . <i>Annals of Neurology</i> , 2012, 71, 370-384. | 5.3 | 264 |
| 6 | Dystonia. <i>New England Journal of Medicine</i> , 2006, 355, 818-829. | 27.0 | 243 |
| 7 | Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2019, 92, 329-337. | 1.1 | 194 |
| 8 | Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 584. | 7.4 | 192 |
| 9 | Mitochondrial Cyclic AMP Response Element-binding Protein (CREB) Mediates Mitochondrial Gene Expression and Neuronal Survival. <i>Journal of Biological Chemistry</i> , 2005, 280, 40398-40401. | 3.4 | 187 |
| 10 | Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. <i>Movement Disorders</i> , 2017, 32, 319-324. | 3.9 | 145 |
| 11 | Association of Cumulative Lead Exposure with Parkinson's Disease. <i>Environmental Health Perspectives</i> , 2010, 118, 1609-1613. | 6.0 | 137 |
| 12 | Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. <i>Movement Disorders</i> , 2019, 34, 1839-1850. | 3.9 | 122 |
| 13 | Noninvasive Brain Stimulation for Parkinson's Disease and Dystonia. <i>Neurotherapeutics</i> , 2008, 5, 345-361. | 4.4 | 121 |
| 14 | Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease. <i>Neurobiology of Aging</i> , 2004, 25, 71-81. | 3.1 | 110 |
| 15 | Genetic risk of Parkinson disease and progression. <i>Neurology: Genetics</i> , 2019, 5, e348. | 1.9 | 109 |
| 16 | Somatic mitochondrial DNA mutations in early parkinson and incidental lewy body disease. <i>Annals of Neurology</i> , 2012, 71, 850-854. | 5.3 | 103 |
| 17 | Responses of retinal axons in vivo and in vitro to position-encoding molecules in the embryonic superior colliculus. <i>Neuron</i> , 1992, 9, 977-989. | 8.1 | 99 |
| 18 | Oral N-Acetyl-Cysteine Attenuates Loss of Dopaminergic Terminals in α -Synuclein Overexpressing Mice. <i>PLoS ONE</i> , 2010, 5, e12333. | 2.5 | 97 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Limited topographic specificity in the targeting and branching of mammalian retinal axons. <i>Developmental Biology</i> , 1990, 137, 125-134. | 2.0 | 96 |
| 20 | A Common NURR1 Polymorphism Associated With Parkinson Disease and Diffuse Lewy Body Disease. <i>Archives of Neurology</i> , 2003, 60, 722. | 4.5 | 90 |
| 21 | Transcribe to Survive: Transcriptional Control of Antioxidant Defense Programs for Neuroprotection in Parkinson's Disease. <i>Antioxidants and Redox Signaling</i> , 2009, 11, 509-528. | 5.4 | 88 |
| 22 | Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease. <i>JAMA Neurology</i> , 2021, 78, 312. | 9.0 | 83 |
| 23 | Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 926. | 7.4 | 80 |
| 24 | Rapamycin drives selection against a pathogenic heteroplasmic mitochondrial DNA mutation. <i>Human Molecular Genetics</i> , 2014, 23, 637-647. | 2.9 | 79 |
| 25 | Somatic mitochondrial DNA mutations in single neurons and glia. <i>Neurobiology of Aging</i> , 2005, 26, 1343-1355. | 3.1 | 77 |
| 26 | Frequency of the D620N Mutation in VPS35 in Parkinson Disease. <i>Archives of Neurology</i> , 2012, 69, 1360. | 4.5 | 76 |
| 27 | An inverse-Warburg effect and the origin of Alzheimer's disease. <i>Biogerontology</i> , 2012, 13, 583-594. | 3.9 | 73 |
| 28 | Relationship of retinotopic ordering of axons in the optic pathway to the formation of visual maps in central targets. <i>Journal of Comparative Neurology</i> , 1991, 307, 393-404. | 1.6 | 67 |
| 29 | Pgc-1 β Overexpression Downregulates Pitx3 and Increases Susceptibility to MPTP Toxicity Associated with Decreased Bdnf. <i>PLoS ONE</i> , 2012, 7, e48925. | 2.5 | 63 |
| 30 | Differences in the Presentation and Progression of Parkinson's Disease by Sex. <i>Movement Disorders</i> , 2021, 36, 106-117. | 3.9 | 54 |
| 31 | Head injury at early ages is associated with risk of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 23, 57-61. | 2.2 | 50 |
| 32 | Plasticity in the Development of Topographic Order in the Mammalian Retinocollicular Projection. <i>Developmental Biology</i> , 1994, 162, 384-393. | 2.0 | 48 |
| 33 | Singing in groups for Parkinson's disease (SING-PD): A pilot study of group singing therapy for PD-related voice/speech disorders. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 548-552. | 2.2 | 48 |
| 34 | Attenuation of free radical production and paracrystalline inclusions by creatine supplementation in a patient with a novel cytochrome b mutation. <i>Muscle and Nerve</i> , 2004, 29, 537-547. | 2.2 | 43 |
| 35 | Influence of position along the medial-lateral axis of the superior colliculus on the topographic targeting and survival of retinal axons. <i>Developmental Brain Research</i> , 1992, 69, 167-172. | 1.7 | 42 |
| 36 | Do mtDNA deletions drive premature aging in mtDNA mutator mice?. <i>Aging Cell</i> , 2009, 8, 502-506. | 6.7 | 40 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | The inverse association of cancer and Alzheimer's: a bioenergetic mechanism. <i>Journal of the Royal Society Interface</i> , 2013, 10, 20130006. | 3.4 | 39 |
| 38 | A heteroplasmic mitochondrial complex I gene mutation in adult-onset dystonia. <i>Neurogenetics</i> , 2003, 4, 199-205. | 1.4 | 38 |
| 39 | Caffeine and Progression of Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2008, 31, 189-196. | 0.7 | 35 |
| 40 | Metabolomic analysis of exercise effects in the POLG mitochondrial DNA mutator mouse brain. <i>Neurobiology of Aging</i> , 2015, 36, 2972-2983. | 3.1 | 34 |
| 41 | Behavioral and metabolic characterization of heterozygous and homozygous POLG mutator mice. <i>Mitochondrion</i> , 2013, 13, 282-291. | 3.4 | 33 |
| 42 | Mitochondrial Complex I Gene Variant Associated With Early Age at Onset in Spinocerebellar Ataxia Type 2. <i>Archives of Neurology</i> , 2007, 64, 1042. | 4.5 | 30 |
| 43 | MELAS syndrome, cardiomyopathy, rhabdomyolysis, and autism associated with the A3260G mitochondrial DNA mutation. <i>Biochemical and Biophysical Research Communications</i> , 2010, 402, 443-447. | 2.1 | 28 |
| 44 | Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. <i>Journal of the Neurological Sciences</i> , 2017, 377, 137-143. | 0.6 | 27 |
| 45 | Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease. <i>BMC Medical Genetics</i> , 2010, 11, 53. | 2.1 | 26 |
| 46 | Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects. <i>Journal of Parkinson's Disease</i> , 2015, 5, 731-736. | 2.8 | 25 |
| 47 | Caffeine and Progression of Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2015, 38, 163-169. | 0.7 | 25 |
| 48 | The c.237_236GA>TT <i>THAP1</i> sequence variant does not increase risk for primary dystonia. <i>Movement Disorders</i> , 2011, 26, 549-553. | 3.9 | 24 |
| 49 | Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores. <i>Neurology</i> , 2017, 89, 1789-1794. | 1.1 | 24 |
| 50 | Caffeine, creatine, GRIN2A and Parkinson's disease progression. <i>Journal of the Neurological Sciences</i> , 2017, 375, 355-359. | 0.6 | 23 |
| 51 | Inverse Probability Weighted Cox Regression for Doubly Truncated Data. <i>Biometrics</i> , 2018, 74, 481-487. | 1.4 | 21 |
| 52 | Mistaken diagnosis of psychogenic gait disorder in a man with status cataplecticus ("Limp Man) Tj ETQq0 0 0 rgBT /Overlock, 10 Tf 50 1 | 3.9 | 20 |
| 53 | Autonomic and electrocardiographic findings in Parkinson's disease. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2017, 205, 93-98. | 2.8 | 19 |
| 54 | VPS35 and the mitochondria: Connecting the dots in Parkinson's disease pathophysiology. <i>Neurobiology of Disease</i> , 2020, 145, 105056. | 4.4 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Somatic mitochondrial DNA mutations do not increase neuronal vulnerability to MPTP in young POLG mutator mice. <i>Neurotoxicology and Teratology</i> , 2014, 46, 62-67. | 2.4 | 14 |
| 56 | Clinical Impact of ¹²³ I-Ioflupane SPECT (DaTscan) in a Movement Disorder Center. <i>Neurodegenerative Diseases</i> , 2017, 17, 38-43. | 1.4 | 13 |
| 57 | Do Somatic Mitochondrial DNA Mutations Contribute to Parkinson's Disease?. <i>Parkinson's Disease</i> , 2011, 2011, 1-9. | 1.1 | 12 |
| 58 | Computationally simple estimation and improved efficiency for special cases of double truncation. <i>Lifetime Data Analysis</i> , 2014, 20, 335-354. | 0.9 | 12 |
| 59 | Complicated spontaneous intracranial hypotension treated with intrathecal saline infusion. <i>Practical Neurology</i> , 2016, 16, 146-149. | 1.1 | 12 |
| 60 | A frameshift mitochondrial complex I gene mutation in a patient with dystonia and cataracts: is the mutation pathogenic?. <i>Journal of Medical Genetics</i> , 2001, 38, 58-61. | 3.2 | 12 |
| 61 | No Sex Differences in Use of Dopaminergic Medication in Early Parkinson Disease in the US and Canada - Baseline Findings of a Multicenter Trial. <i>PLoS ONE</i> , 2014, 9, e112287. | 2.5 | 12 |
| 62 | Altered muscle electrical tissue properties in a mouse model of premature aging. <i>Muscle and Nerve</i> , 2019, 60, 801-810. | 2.2 | 11 |
| 63 | Genetic risk factors in Parkinson's disease: single gene effects and interactions of genotypes. <i>Journal of Neurology</i> , 2012, 259, 2503-2505. | 3.6 | 7 |
| 64 | Mitochondrial DNA mutations in Parkinson's disease brain. <i>Acta Neuropathologica Communications</i> , 2017, 5, 33. | 5.2 | 7 |
| 65 | Transportation innovation to aid Parkinson disease trial recruitment. <i>Contemporary Clinical Trials Communications</i> , 2019, 16, 100449. | 1.1 | 6 |
| 66 | Acute readmission following deep brain stimulation surgery for Parkinson's disease: A nationwide analysis. <i>Parkinsonism and Related Disorders</i> , 2020, 70, 96-102. | 2.2 | 6 |
| 67 | Efficacy of Deep Brain Stimulation in a Patient with Genetically Confirmed Chorea-Acanthocytosis. <i>Case Reports in Neurology</i> , 2019, 11, 199-204. | 0.7 | 5 |
| 68 | Boxing Exercises as Therapy for Parkinson Disease. <i>Topics in Geriatric Rehabilitation</i> , 2020, 36, 160-165. | 0.4 | 4 |
| 69 | Mitochondria and Parkinson's Disease. <i>Parkinson's Disease</i> , 2011, 2011, 1-2. | 1.1 | 3 |
| 70 | The Relationship Between Olfactory Dysfunction and Constipation in Early Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 781-782. | 3.9 | 3 |
| 71 | Novel human pathological mutations. Gene symbol: THAP1. Disease: dystonia 6. <i>Human Genetics</i> , 2010, 127, 470. | 3.8 | 1 |
| 72 | The utility of laser-generated visual-cueing in Parkinsonian patients with gait freezing. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 401. | 2.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | A New Approach to the Development of <scp>Diseaseâ€Modifying</scp> Therapies for <scp>PD</scp>. Movement Disorders, 2021, 36, 1281-1281. | 3.9 | 0 |
| 74 | Associations between exercise classes and self-reported exercise by people with Parkinsonâ€™s disease at Parkinsonâ€™s foundation centers of excellence. Clinical Parkinsonism & Related Disorders, 2022, 6, 100137. | 0.9 | 0 |